- Home
- ELBM vs DXR Comparison
ELBM vs DXR Comparison
Compare ELBM & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELBM | DXR |
|---|---|---|
| Founded | 2011 | 1970 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 71.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ELBM | DXR |
|---|---|---|
| Price | $0.84 | $12.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.15 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.7M | 8.0K |
| Earning Date | 03-27-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $34.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.77 | $6.55 |
| 52 Week High | $8.70 | $14.76 |
Technical Indicators
Market Signals| Indicator | ELBM | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 44.66 |
| Support Level | $0.98 | $12.15 |
| Resistance Level | $0.93 | $12.74 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.87 | 14.07 |
Price Performance
Historical ComparisonAbout ELBM Electra Battery Materials Corporation
Electra Battery Materials Corp is building North America's fully integrated, localized, and environmentally sustainable battery materials park. Electra Battery Materials is an integral part of the North American battery supply chain, providing low-carbon, sustainable, and traceable raw materials for the region's fast growing electric vehicle industry.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.